Advertisement
Advertisement
U.S. markets close in 1 hour 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Intellipharmaceutics International Inc. (IPCI.TO)

Toronto - Toronto Real Time Price. Currency in CAD
0.1050+0.0050 (+5.00%)
As of 12:52PM EST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1000
Open0.1050
Bid0.1050 x 0
Ask0.1100 x 0
Day's Range0.1050 - 0.1050
52 Week Range0.1000 - 0.3900
Volume500
Avg. Volume2,290
Market Cap3.475M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.2120
Earnings DateOct 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for IPCI.TO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ACCESSWIRE

      Intellipharmaceutics Announces Third Quarter 2022 Results

      - Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2022.

    • ACCESSWIRE

      Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets

      Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc. ("Taro"), by which the Company has granted Taro an exclusive license to

    • ACCESSWIRE

      Intellipharmaceutics Announces Second Quarter 2022 Results

      Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2022. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

    Advertisement
    Advertisement